ZIOPHARM Oncology, Inc. Stock price
Is ZIOPHARM Oncology, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.
Key metrics
ZIOPHARM Oncology, Inc. Stock Analysis
Analyst Opinions
6 Analysts have issued a ZIOPHARM Oncology, Inc. forecast:
Analyst Opinions
6 Analysts have issued a ZIOPHARM Oncology, Inc. forecast:
Don't miss a Thing! We will send you all news about ZIOPHARM Oncology, Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ZIOPHARM Oncology, Inc. Stock News
Company Profile
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline include Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.
| Head office | United States |
| CEO | Mr. Weis |
| Employees | 1 |
| Founded | 2003 |
| Website | alaunos.com |


